EU/3/17/1860: Orphan designation for the treatment of ovarian cancer

Poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate

Table of contents

Overview

On 20 March 2017, orphan designation (EU/3/17/1860) was granted by the European Commission to Viadoc Business Solutions Limited, United Kingdom, for poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate (also known as CRLX101) for the treatment of ovarian cancer.

Key facts

Active substance
Poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate
Intended use
Treatment of ovarian cancer
Orphan designation status
Positive
EU designation number
EU/3/17/1860
Date of designation
20/03/2017
Sponsor
Viadoc Business Solutions Limited
C/O Oakwood Corporate Services
1 Ashley Road, 3rd floor
Altrincham, Cheshire
WA14 2DT
United Kingdom
Tel. +44 (0)161 942 4702
E-mail: patti@viadoc.net

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating